远大医药(00512.HK)拟2500万美元购买美国生物医药公司OncoSec 44.2%股权
格隆汇10月10日丨远大医药(00512.HK)公布，于2019年10月10日，本公司直接全资拥有附属公司弘年与OncoSec订立了远大股份购买协议，据此弘年有条件同意以代价2500万美元购买1000万股OncoSec股份，代表经远大股份购买事项及Sirtex股份购买事项扩大后OncoSec股本的约44.2%。
按本公司所得悉，于2019年10月10日，Sirtex亦与OncoSec订立了Sirtex股份购买协议，以每股购买价2.5美元购买200万股OncoSec股份。Sirtex购买的2,000,000股OncoSec股份代表经远大股份购买事项及Sirtex股份购买事项扩大后的OncoSec股本的约8.8%。远大股份购买事项及Sirtex股份购买事项的完成条件是互为条件的，并预期会同时发生。
据悉，OncoSec为一间于美国内华达州成立的公司并于Nasdaq上市，是一间已进行临床阶段的生物技术公司，主要为开发细胞激素为基础的肿瘤内免疫疗法，使用新技术以刺激人体的免疫系统以靶向攻击癌症。OncoSec于截至2017年及2018年7月31日止年度分别亏损2140万美元及3910万美元。
按董事所知，OncoSec为一间已进入临床阶段的创新生物技术公司，主要为开发细胞激素为基础的肿瘤内免疫疗法，使用其专有的电穿孔传递技术以刺激人体的免疫系统，并逆转肿瘤治疗中的免疫抑制微环境，活化免疫细胞以达到靶向并攻击肿瘤细胞的目的。
OncoSec的首创免疫疗法产品–TAVO(Tavokinogene Telseplasmid)使以DNA为基础的白介素-12(IL-12)能够在肿瘤及其微环境中持续表达IL-12，以引发身体的免疫反应。IL-12是体内自有的促炎细胞因子，可以提高肿瘤局部的免疫原性并增加肿瘤浸润淋巴细胞(TIL)，促进T细胞向肿瘤浸润。
董事相信远大股份购买协议连同授权协议下的交易可以向本公司提供潜在全球首创的癌症基因治疗产品的系列，例如TAVO、VLA以及OncoSec研发中的其他产品。本公司于中国进行创新医学产品的研发、学术推广及产品上市有充足的经验，并可运用其成熟的销售网络。本公司可预见引入OncoSec的产品到中国及其他亚洲国家有重大潜力，同时有助于进一步丰富本公司创新产品的储备，加快本公司向国际化及研发创新转型的步伐。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
